D-0222-2024 Class II Ongoing

Recalled by Rising Pharma Holding, Inc. — East Brunswick, NJ

FDA drug recall D-0222-2024 was initiated by Rising Pharma Holding, Inc. on Dec 29, 2023 and is designated Class II. Reason for recall: Presence of Foreign Tablets/Capsules The recall status is ongoing. Affected quantity: 47,976 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 17, 2024
Initiation Date
Dec 29, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
47,976 bottles

Product description

buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx Only, Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Manufactured by: Graviti Pharmaceuticals Pvt. Ltd. Telangana - 502307, INDIA, NDC 16571-862-03

Reason for recall

Presence of Foreign Tablets/Capsules

Distribution pattern

Nationwide within the United States

Code information

Lot #: BPA123098A, Exp. Date 06/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0222-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0222-2024. Report a data issue: hello@regdatalab.com.